$RLYB News

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio To Acquire Avenzo Therapeutics; Avenzo Entered Into $215M Private Placement Financing

RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters

Rallybio to acquire Candid Therapeutics

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio shares are trading higher after the company agreed to a merger deal with Candid Therapeutics.

Rallybio shares are trading higher after the company agreed to a merger deal with Candid Therapeutics.

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Candid, in a reverse merger with RallyBio, to go public

Rallybio Corporation Shares Resume Trade

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Rallybio To Acquire Candid Therapeutics Under All-Stock Merger Agreement

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Rallybio Reports Results From Phase 1 Confirmatory PK/PD Clinical Trial Evaluating RLYB116 In Development For Patients With Complement-Mediated Diseases With Initial Focus On Immune PTR And Refractory APS

Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Announces 1-For-8 Reverse Stock Split

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates